The Inspirational Quest to Eradicate Cancer

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day.

Dr. Bepler arrived from Germany to the United States in 1983. Following a post-doctoral fellowship at the National Cancer Institute, the starting point for his journey into lung cancer research. This career path took Dr. Bepler through many stops along the way, and in 2010 he joined the Karmanos Cancer Institute.

The mission to eradicate cancer got a boost in 1971 with the National Cancer Act, and Dr. Bepler said there’s tremendous progress towards this goal since that point. “People now diagnosed with cancer have hope,” Dr. Bepler said. “And many of them get cured of the disease and have a good quality of life. That all wouldn’t have been possible without the National Cancer Act.”

Much of the progress made to eradicating cancer at the Karmanos Cancer Institute owes a debt of gratitude to that 50-year-old law for providing necessary funding that makes such research possible.

“The Karmanos Cancer Institute became one of the NCI designated cancer centers,” Dr. Bepler said. “Very quickly, the National Cancer Institute realized just having one cancer institute in Bethesda, Maryland alone wouldn’t be able to achieve that high goal of eradicating cancer. This network established cancer centers throughout the United States.” What started as a couple of centers in the 1970s is now more than 50 comprehensive cancer centers.

The world now possesses many drugs and treatments to treat cancer through the dedication and research of institutes like the Karmanos Center. And some research led to treatments for other diseases. Dr. Bepler mentioned the Karmanos Center developed three of the first FDA-approved AIDS drugs.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Follow us on social media for the latest updates in B2B!

Image

Latest

teacher
Building the Next Generation of Educators Through Apprenticeship Pathways and Workforce-Aligned Training
March 23, 2026

Teacher shortages aren’t exactly a new headline—but lately, they’ve started to feel a lot more urgent. In some places, schools have gone years without enough fully trained teachers in the classroom, exposing real flaws in how we prepare and retain educators. Add in the rising cost of becoming a teacher and training models that haven’t…

Read More
Joint Commission 360
Understanding Joint Commission 360 Standards: What They Mean for SPD Teams (Part 1)
March 17, 2026

For a long time, compliance in healthcare was tied to the survey cycle. Now, that model is shifting. With the introduction of Joint Commission 360, organizations are being asked to demonstrate continuous performance—not just preparedness. As patient safety comes under increasing scrutiny, The Joint Commission is moving toward an approach built on real-time data, traceability,…

Read More
university
The Employer University Alignment Journey with Kristen Fox, CEO of Business-Higher Education Forum
March 16, 2026

Across the U.S., the conversation about the value of a college degree is increasingly tied to one central question: Does higher education actually prepare students for the workforce? As artificial intelligence reshapes how work gets done and employers rethink the skills they need, universities are under growing pressure to ensure graduates leave not just…

Read More
private equity
How AI Is Transforming Private Equity Deal Evaluation and Portfolio Strategy
March 13, 2026

Artificial intelligence is rapidly transforming how organizations evaluate risk, analyze markets, and drive operational efficiency. In financial services alone, global AI spending is projected to surpass $97 billion by 2027, reflecting how deeply data-driven technologies are reshaping decision-making. For private equity firms—where hundreds of potential investments may be screened each year—the ability to analyze information…

Read More